LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Abivax SA Sponsored ADR today and set a price target of $170.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sam Slutsky has given his Buy rating due to a combination of factors that highlight the potential growth and strategic positioning of Abivax SA. The company has experienced a notable increase in its share price following the positive Phase 3 induction data for obefazimod in ulcerative colitis. This development has sparked investor interest, with many speculating on a potential acquisition by a larger pharmaceutical company, as has been the trend with other inflammatory bowel disease treatments.
Additionally, Slutsky points to several upcoming catalysts that could further enhance Abivax’s market value, including Phase 3 maintenance data for ulcerative colitis and Phase 2 data for Crohn’s disease. The analyst has adjusted the financial model to reflect a lower discount rate, acknowledging the advanced stage of Abivax’s product development. This adjustment has led to an increased price target, indicating confidence in the company’s future performance. The promising sales projections for obefazimod, along with its unique delivery method, strong efficacy, and favorable safety profile, further support the Buy rating.